Tag Archive for: Destiny Pharma

Destiny Pharma’s SAB Member Professor Dale Gerding is Keynote Speaker at C. diff. International Conference

/in

Brighton, United Kingdom – 4th November 2021 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, today announces that its Scientific Advisory Board Member, Professor Dale Gerding, MD, MACP, FIDSA, FSHEA, will be giving a keynote presentation at the C. diff International Conference & Health EXPO […]

Read more

Destiny Pharma: Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus

/in

Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus Strong support for potential of XF-73 nasal product as alternative to mupirocin Brighton, United Kingdom – 18 October 2021 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life […]

Read more

Destiny Pharma’s Call to Arms to Combat AMR

/in

CEO Neil Clark and CSO Dr Bill Love from Europe’s leading anti-infectives biotech company Destiny Pharma, on how the makers and influencers of health policy could fuel a renaissance in drug development…

Read more